186534-02-1|3,5,6-Trimethylpyrazine-2-carbaldehyde| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 186534-02-1 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 186534-02-1 ]

CAS No. :	186534-02-1
Formula :	C₈H₁₀N₂O
M.W :	150.18
SMILES Code :	O=CC1=NC(C)=C(C)N=C1C
MDL No. :	MFCD16294231
InChI Key :	HSGOLPGJARMUOX-UHFFFAOYSA-N
Pubchem ID :	18455001

Safety of [ 186534-02-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 186534-02-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.38
Num. rotatable bonds	1
Num. H-bond acceptors	3.0
Num. H-bond donors	0.0
Molar Refractivity	42.32
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	42.85 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.36
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.78
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.21
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.42
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.35
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.06

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.6
Solubility	3.77 mg/ml ; 0.0251 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.26
Solubility	8.24 mg/ml ; 0.0549 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.74
Solubility	0.271 mg/ml ; 0.0018 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.66 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.75

Application In Synthesis of [ 186534-02-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 186534-02-1 ]

[ 186534-02-1 ] Synthesis Path-Downstream 1~35

1
[ 16649-50-6 ]
[ 186534-02-1 ]
[ 1083171-75-8 ]

Yield	Reaction Conditions	Operation in experiment
38%	In methanol;Reflux;	Example 1 Synthesis of TBN (FIG. 2) 2-[[(1,1-Dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine (TBN). To aldehyde 5 (1.9 g, 0.013 mol) in methanol (200 mL) was added tert-butylhydroxylamine (1 g, 0.011 mol), and the solution was refluxed for 2 h. Another portion of tert-butyl hydroxylamine (1 g, 0.011 mol) was then added, and the solution refluxed until aldehyde 5 was completely reacted. Solvent was removed in vacuo, and the product was extracted. The solution was dried with Na2SO4, and solvent removed in vacuo. The product was purified by column chromatography, eluding with ethyl acetate/petroleum ether (1/1, v/v), to produce TBN as a light yellow solid (1.1 g, 38% yield), mp: 68-70 C. 1H NMR (CDCl3, ppm): 7.82 (s, 1H), 2.47 (s, 3H), 2.50 (s, 3H), 2.52 (s, 3H), 1.63 (s, 9H). ESI-MS: 222 [M+H]+, 244 [M+Na]+. Anal. (C12H19N3O) C, H, N.
38%	In mthanol;Reflux;	To aldehyde 5 (1.9 g, 0.013 mol) in methanol (200 mL) was added tert-butylhydroxylamine (1 g, 0.011 mol), and the solution was refluxed for 2 h. Another portion of tert-butyl hydroxy lamine (1 g, 0.011 mol) was then added, and the solution refluxed until aldehyde 5 was completely reacted. Solvent was removed in vacuo, and the product was extracted. The solution was dried with Na2SO4, and solvent removed in vacuo. The product was purified by column chromatography, eluting with ethyl acetate/petroleum ether (1/1, v/v), to produce TBN as a light yellow solid (1.1 g, 38% yield), mp: 68-70 0C. 1H NMR (CDCl3, ppm): 7.82 (s, IH), 2.47 (s, 3H), 2.50 (s, 3H), 2.52 (s, 3H), 1.63 (s, 9H). ESI-MS: 222 [M+H]+, 244 [M+Na]+. Anal. (Ci2H19N3O) C, H, N.

References: [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 8868 - 8874.
[2]Patent: US2011/34485,2011,A1 .Location in patent: Page/Page column 7.
[3]Patent: WO2009/129726,2009,A1 .Location in patent: Page/Page column 17-18.

2
[ 186534-02-1 ]
[ 186534-01-0 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium chlorite; 2-methyl-but-2-ene; In water; tert-butyl alcohol; at 0 - 20℃; for 0.833333h;	To a solution of 3,5,6-trimethylpyrazine-2-carbardehyde (4.51 g, 30.0 mmol), 2- methyl-2-butene (12.8 mL, 120 mmol), and sodium dihydrogen phosphate 78ehydrate (4.68 g, 30.0 mmol) in /ert-butanol (90 mL) and water (30 mL) was added 80% sodium chlorite (10.2 g, 90.0 mmol) portionwise at 0 C. After being stirred at room temperature for 50 min, the reaction mixture was poured into 2N aqueous hydrochloric acid. The mixture was extracted with chloroform and the organic layer was dried over sodium sulfate, filtrated and concentrated in vacuo to give 3,5,6- trimethylpyrazine-2-carboxylate. MS (ESI): m/z 165 (M-H).

References: [1]Patent: WO2011/105628,2011,A1 .Location in patent: Page/Page column 78.

3
[ 186534-02-1 ]
[ 1332730-39-8 ]

References: [1]Patent: WO2011/105628,2011,A1 .

4
[ 75907-74-3 ]
[ 186534-02-1 ]

Yield	Reaction Conditions	Operation in experiment
93.9%	With manganese(IV) oxide; In ethanol; for 12h;Reflux;	Reaction step 2-hydroxymethyl-3,5,6-trimethylpyrazine (9.5 g, 62.5 mmol) was sequentially added to a 250 mL three-necked flask,MnO2 (16.2 g, 187.5 mmol),Ethanol 100mL,Reflux 12h,TLC (petroleum ether - ethyl acetate 2: 1) detection reaction is almost complete,cool down,Filtering to obtain filtrate,Ethanol recovery under reduced pressure,To give a yellow solid,Purification by silica gel column chromatography (petroleum ether-ethyl acetate 4: 1)3,5,6-trimethylpyrazine-2-carbaldehyde as a pale yellow solid,The yield was 93.9%
93.9%	With manganese(IV) oxide; In ethanol; for 12h;Reflux;	Were added 2-hydroxymethyl-3,5,6-trimethyl pyrazine in 250mL three-necked flask (9.5g, 62.5mmol), MnO2(16.2g, 187.5mmol), ethanol 100mL, refluxed for 12h, TLC (petroleum ether - ethyl acetate 2: 1) detecting the reaction is substantially complete, cooled, filtered, recovering ethanol under reduced pressure to give a yellow solid by silica gel column chromatography (petroleum ether - ethyl acetate 4: 1) to give 8.8 g of a pale yellow solid, yield 93.9%.
90%	With manganese(IV) oxide; In ethanol; for 6h;Reflux;	Weigh 2-hydroxymethyl-3,5,6-trimethylpyrazine (3.0 g, 25 mmol),Dissolved in 50mL of absolute ethanol,Manganese dioxide powder (4.34 g, 50 mmol) was added with stirring.The reaction was carried out under heating and reflux for 6 h.Cooling the reaction solution,Add diatomaceous earth and filter under reduced pressure.After the filter cake is rinsed with ethanol,Merged with the filtrate,Evaporation of the solvent gave a pale yellow solid.Is a crude product of 3,5,6-trimethylpyrazine-2-formaldehyde,Then perform rapid column chromatography separation,Light yellow solid,That is pure 3,5,6-trimethylpyrazine-2-carboxaldehyde,Yield 90%,Melting point 84-85 C.

75%	With manganese(IV) oxide; In ethanol; at 84℃; for 2h;	The obtained 7.5 g of TMP-OH (49.3 mmol) was dissolved in 50 ml of absolute ethanol to add active manganese dioxide.(6.4g, 73.6mmol) was oxidized and reacted in an oil bath at 84 C for 2 h. After the TLC reaction was completed,The reaction solution was carefully filtered with a five-layer filter paper while hot, and the manganese dioxide powder was removed.After filtration, a clear filtrate was obtained, which was evaporated to dryness under reduced pressure on a rotary evaporator. Wet loading column chromatography:The mobile phase EA:PE (1:5) was separated and purified, and the fraction was monitored by TLC. Collecting the compound 1a-4 fraction,Combine the same fraction and distill it to obtain a crystalline white solid.5.5g (36.7mmol),[M+H]+=151 is 1a-4 (TMP-CHO), yield 75%.
70%	With manganese(IV) oxide; In chloroform; for 6h;Reflux;	Compound 1a (6.08 g, 40 mmol) was dissolved in CHCl3 (60 mL),MnO2 (24 g, 280 mmol) was added, and the mixture was refluxed for 6 h, cooled, filtered, and concentrated. The crude productwas purified by column chromatography and eluted with ethyl acetate-petroleum ether (1:6) to yield 1b as bright yellowcrystals (4.2 g, 70%), mp 86C. ESI-MS m/z 151 [M + 1]+, C8H10N2O. 1H NMR (500 MHz, CDCl3, , ppm): 10.10 (1H, s,CHO), 2.75 (3H, s, CH3), 2.56 (6H, s, CH3 2). 13C NMR (125 MHz, CDCl3, , ppm): 21.39, 22.18, 141.91, 149.98, 151.54,155.45, 194.33.
66%	With manganese(IV) oxide; In ethanol; for 3h;Reflux;	In a 50 ml round-bottom flask the compound TMP-OH (1.52 g 10 mmol) was added and dissolved in 20 mL of anhydrous ethanol active manganese dioxide (2.61 g 30 mmol) was added heated to reflux for 3 hours and monitored by TLC until the starting material completely comsumed and the resulting material was filtered and concentrated and separated with column chromatography eluted with ethyl acetate /petroleum ether (11) to give the compound TMP-CHO as a white solid (0.99 g 66) .
66%	With manganese(IV) oxide; In ethanol; for 3h;Reflux;	In a 50 ml round-bottom flask, the compound TMP-OH (1.52 g, 10 mmol) was added and dissolved in 20 mE of anhydrous ethanol, active manganese dioxide (2.61 g, 30 mmol) was added, heated to reflux for 3 hours, and monitored by TEC until the starting material completely consumed, and the resulting material was filtered and concentrated, and separated with colunm chromatography eluted with ethyl acetate/petroleum ether (1:1) to give the compound TMP-CHO as a white solid (0.99 g, 66%).
	With manganese(IV) oxide; In dichloromethane; at 20℃; for 72h;	A suspension of 3,5,6-trimethylpyrazine-2-yl)methanol (see Bioorg. Med. Chem. 2007, 15, 3315; 14.8 g, 97.2 mmol) and manganes(IV) oxide (30.0 g) in dichloromethane was stirred at room temperature for 3 days. The reaction mixture was filtrated through Celite with dichloromethane. The filtrate was combined and concentrated in vacuo to give 3,5,6-trimethylpyrazine-2-carbardehyde. MS (APCI): m/z 151 (M+H).

References: [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 1747 - 1760.
[2]Heterocyclic Communications,2015,vol. 21,p. 335 - 336.
[3]Patent: CN105237487,2016,A .Location in patent: Paragraph 0038; 0039; 0040; 0041.
[4]Patent: CN106518791,2017,A .Location in patent: Paragraph 0045-0049.
[5]Patent: CN108484511,2018,A .Location in patent: Paragraph 0024; 0025; 0026; 0028.
[6]Journal of Medicinal Chemistry,2018,vol. 61,p. 1821 - 1832.
[7]Patent: CN103804309,2019,B .Location in patent: Paragraph 0087; 0089.
[8]Chemistry of Natural Compounds,2017,vol. 53,p. 114 - 117.
Khim. Prir. Soedin.,2017,vol. 53,p. 96 - 98,3.
[9]Patent: WO2015/109935,2015,A1 .Location in patent: Page/Page column 18.
[10]Patent: US2016/326099,2016,A1 .Location in patent: Paragraph 0109.
[11]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.
[12]Patent: WO2011/105628,2011,A1 .Location in patent: Page/Page column 78.
[13]European Journal of Medicinal Chemistry,2017,vol. 135,p. 34 - 48.
[14]Chemical Biology and Drug Design,2018,vol. 92,p. 1859 - 1866.
[15]Patent: US2018/346430,2018,A1 .Location in patent: Paragraph 0038.
[16]Patent: US2019/218192,2019,A1 .Location in patent: Paragraph 0038.
[17],2020,vol. 11,p. 826 - 829.

5
[ 1124-11-4 ]
[ 186534-02-1 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.
[2]MedChemComm,2015,vol. 6,p. 586 - 591.
[3]Patent: WO2015/109935,2015,A1 .
[4]Journal of Medicinal Chemistry,2016,vol. 59,p. 1747 - 1760.
[5]Patent: CN105237487,2016,A .
[6]Patent: US2016/326099,2016,A1 .
[7]European Journal of Medicinal Chemistry,2017,vol. 135,p. 34 - 48.
[8]Patent: CN106518791,2017,A .
[9]Chemistry of Natural Compounds,2017,vol. 53,p. 114 - 117.
Khim. Prir. Soedin.,2017,vol. 53,p. 96 - 98,3.
[10]Journal of Medicinal Chemistry,2018,vol. 61,p. 1821 - 1832.
[11]Patent: CN108484511,2018,A .
[12]Chemical Biology and Drug Design,2018,vol. 92,p. 1859 - 1866.
[13]Patent: US2018/346430,2018,A1 .
[14]Patent: US2019/218192,2019,A1 .
[15]Patent: CN103804309,2019,B .
[16],2020,vol. 11,p. 826 - 829.

6
[ 186534-02-1 ]
[ 54049-93-3 ]
[ 1000672-87-6 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.

7
[ 186534-02-1 ]
[ 3762-25-2 ]
[ 1000672-80-9 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.

8
[ 186534-02-1 ]
[ 62778-16-9 ]
[ 1000672-79-6 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.

9
[ 186534-02-1 ]
[ 23973-65-1 ]
[ 1000672-86-5 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.

10
[ 22978-83-2 ]
[ 186534-02-1 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 731 - 739.
[2]Patent: CN105237487,2016,A .
[3]Patent: CN106518791,2017,A .
[4]Chemistry of Natural Compounds,2017,vol. 53,p. 114 - 117.
Khim. Prir. Soedin.,2017,vol. 53,p. 96 - 98,3.
[5]Journal of Medicinal Chemistry,2018,vol. 61,p. 1821 - 1832.
[6]Patent: CN108484511,2018,A .
[7]Chemical Biology and Drug Design,2018,vol. 92,p. 1859 - 1866.

11
[ 186534-02-1 ]
4-((2R)-2-acetoxy-3-oxo-3-(1-(3,5,6-trimethylpyrazin-2-yl)ethoxy)propyl)-1,2-phenylene diacetate [ No CAS ]

References: [1]MedChemComm,2015,vol. 6,p. 586 - 591.

12
[ 186534-02-1 ]
4-((2R)-2-acetoxy-3-oxo-3-((1-(3,5,6-trimethylpyrazin-2-yl)but-3-en-1-yl)oxy)propyl)-1,2-phenylene diacetate [ No CAS ]

References: [1]MedChemComm,2015,vol. 6,p. 586 - 591.

13
[ 186534-02-1 ]
[ 75-16-1 ]
1-(3,5,6-trimethylpyrazin-2-yl)ethanol [ No CAS ]

References: [1]MedChemComm,2015,vol. 6,p. 586 - 591.

14
[ 186534-02-1 ]
[ 1730-25-2 ]
1-(3,5,6-trimethylpyrazin-2-yl)but-3-en-1-ol [ No CAS ]

References: [1]MedChemComm,2015,vol. 6,p. 586 - 591.

15
[ 186534-02-1 ]
C₁₂H₁₇N₃ [ No CAS ]

References: [1]Patent: WO2015/109935,2015,A1 .
[2]Patent: US2016/326099,2016,A1 .

16
[ 186534-02-1 ]
C₁₄H₁₇N₃ [ No CAS ]

References: [1]Patent: WO2015/109935,2015,A1 .
[2]Patent: US2016/326099,2016,A1 .

17
[ 186534-02-1 ]
[ 2450-71-7 ]
C₁₁H₁₅N₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
86%		In a 50 mL round-bottom flask freshly prepared TMP-CHO (150 mg 1 mmol) was added and dissolved in 20 mL of 1 2-dichloroethane propargylamine (66 mg 1.2 mmol) was added slowly at room temperature the reaction was run at at room temperature for 2 hours triacetoxy sodium borohydride (424 mg 2 mmol) was added and monitored by TLC about 2 hours later the reaction was complete 10 mL of 10 K2CO3was added for quenching. The resulting material was extracted with dichloromethane dried over anhydrous sodium sulfate filtered and concentrated and purified with silica gel column chromatography (ethyl acetatepetroleum ether 32) to give the compound MT-012 as a yellow solid (163mg 86) . ESI-MS [M+H]+m/z 190.3.1H-NMR (CDCl3) 3.96 (s 2H) 3.56 (d J2.4 Hz 2H) 2.51 (s 3H) 2.49 (s 6H) 2.26 (t J2.4 Hz 1H) .
86%	In 1,2-dichloro-ethane; at 20℃; for 2h;	10110] In a 50 mE round-bottom flask, freshly prepared TMP-CHO(lSOmg, 1 mmol)was addedanddissolvedin20 mE of 1 ,2-dichloroethane, propargylamine (66 mg, 1.2 mmol) was added slowly at room temperature, the reaction was run at room temperature for 2 hours, triacetoxy sodium borohydride (424 mg, 2 mmol) was added and monitored by TEC, about 2 hours later the reaction was complete, 10 mE of 10% K2C03 was added for quenching. The resulting material was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered and concentrated, and purified with silica gel colunm chromatography (ethyl acetate:petroleum ether 3:2) to give the compound MT-012 as a yellow solid (163 mg, 86%). ESI-MS: [M+H] mlz 190.3. ?H-NMR (CDC13): 3.96 (s, 2H); 3.56 (d, J=2.4 Hz, 2H); 2.51 (s, 3H); 2.49 (s, 6H); 2.26 (t, J=2.4 Hz, 1H).

References: [1]Patent: WO2015/109935,2015,A1 .Location in patent: Page/Page column 18.
[2]Patent: US2016/326099,2016,A1 .Location in patent: Paragraph 0110.

18
[ 59-48-3 ]
[ 186534-02-1 ]
colletotrichumine A [ No CAS ]